Siraitia grosvenorii is a premier food-medicine homologous species recognised by China’s National Health Commission and produces mogrosides as its primary active component.These compounds exhibit biological activitie...Siraitia grosvenorii is a premier food-medicine homologous species recognised by China’s National Health Commission and produces mogrosides as its primary active component.These compounds exhibit biological activities,including the regulation of blood sugar,fat metabolism,and immune function regulation.They are classified as high-intensity,non-nutritive sweeteners with significant medicinal potential and nutritional value.This review systematically explores the applications of S.grosvenorii in traditional medicine and foods,with a focus on advances in the conservation of germplasm resources and the traditional breeding of elite varieties,mogroside biosynthetic pathways and the characterization of key genes,and synthetic biology platforms for mogroside production.We have identified the low content of mogroside V in S.grosvenorii as the main reason for its limited application.To address this issue,we propose two strategic approaches:enhancing mogroside content in vivo through molecular design breeding and developing three synthetic biology platforms for mogrosides synthesis to increase yields.These solutions offer viable ways to reduce production costs and expand the commercial use of S.grosvenorii medicines and sweeteners.展开更多
基金supported by Beijing Natural Science Foundation(No.7252244)Guangxi Key R&D Program(No.GuiKe AB25069119)+3 种基金The Special Funds of Basic Scientific Research Foundation of Guangxi Academy of Agricultural Sciences(No.Gui Nong Ke 2024YP091)Yuelushan Laboratory Breeding Program(No.YLS-2025-ZY04058)The National Natural Science Foundation of China(Nos.82104548,U20A2004,32270398)CAMS Innovation Fund for Medical Sciences(CIFMS)(No.2021-I2M-1-071).
文摘Siraitia grosvenorii is a premier food-medicine homologous species recognised by China’s National Health Commission and produces mogrosides as its primary active component.These compounds exhibit biological activities,including the regulation of blood sugar,fat metabolism,and immune function regulation.They are classified as high-intensity,non-nutritive sweeteners with significant medicinal potential and nutritional value.This review systematically explores the applications of S.grosvenorii in traditional medicine and foods,with a focus on advances in the conservation of germplasm resources and the traditional breeding of elite varieties,mogroside biosynthetic pathways and the characterization of key genes,and synthetic biology platforms for mogroside production.We have identified the low content of mogroside V in S.grosvenorii as the main reason for its limited application.To address this issue,we propose two strategic approaches:enhancing mogroside content in vivo through molecular design breeding and developing three synthetic biology platforms for mogrosides synthesis to increase yields.These solutions offer viable ways to reduce production costs and expand the commercial use of S.grosvenorii medicines and sweeteners.
